Moffat: One of the things that we talked a little bit about is how do we reduce time to market for some of these new therapies? And just wanted to ask if there were any sort of final thoughts on that part of it because better sequencing, better AI, better predictions for viable drugs. Moffat: We think there could be like a 25% time to market reduction with some of these convergences and maybe even a 25% failure rate so less drugs that go into the clinic that ultimately may not work.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode